ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1669

Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
Abstract Number: 2651

Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Abstract Number: 2550

Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic
Abstract Number: 0260

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Abstract Number: 1073

Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
Abstract Number: 0777

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Abstract Number: 2114

Development of a Fracture Prediction Model for Patients Aging with HIV
Abstract Number: 2027

Development of a multi-disease panel for autoimmune diseases
Abstract Number: 0018

Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
Abstract Number: 0213

Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Abstract Number: 0689

Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
Abstract Number: 0538

Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
Abstract Number: 2469

Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Abstract Number: 0910

Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
Abstract Number: 2541

Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].